NCT03421977View on ClinicalTrials.gov

Long-Term Follow-up Study for Patients From AVXS-101-CL-101

Active, not recruitingOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

December 2, 2030

Study Completion Date

December 2, 2030

Conditions
Spinal Muscular Atrophy 1
Interventions
BIOLOGICAL

Onasemnogene Abeparvovec-xioi

Patients received treatment with onasemnogene abeparvovec-xioi in the parent study, AVXS-101-CL-101

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

Sponsors
All Listed Sponsors
lead

Novartis Gene Therapies

INDUSTRY